Lenalidomid Pharmevid

Lenalidomide, the active ingredient in Lenalidomid Pharmevid, is an immunomodulatory drug presented as an oral tablet for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomid Pharmevid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable supply chains and responsive technical support.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.

Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients with relapsed or refractory disease. Myelodysplastic Syndromes: reduces transfusion dependence and modifies disease course in patients with del(5q) cytogenetic abnormality. Mantle Cell Lymphoma: contributes to disease control when combined with other agents in relapsed or refractory adult cases.

Adverse reactions may occur with lenalidomide therapy.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Diarrhea: loose stools that may require supportive care. - Rash: mild skin eruptions that are usually self‑limiting. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia or thrombocytopenia: markedly low blood cell counts. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: significant liver enzyme elevations. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Safety considerations are essential when prescribing lenalidomide.

Monitor blood counts: perform regular CBC to detect cytopenias. Assess thrombotic risk: evaluate history of clotting and consider prophylaxis. Avoid in pregnancy: teratogenic; contraindicated for women of childbearing potential. Use effective contraception: both male and female patients must employ reliable methods. Adjust for renal impairment: dose modifications may be required in reduced kidney function. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide may interact with several concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Other teratogenic agents: additive risk of fetal harm.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug levels. - P‑glycoprotein inhibitors (e.g., verapamil): modest increase in exposure. - Live vaccines: potential for reduced vaccine efficacy. - NSAIDs: may increase risk of thrombosis when combined with lenalidomide.